logo

DermNet NZ

  

Facts about the skin from DermNet New Zealand Trust. Topic index: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z


Intralesional steroid injection

Intralesional steroid injectioninvolves a corticosteroid such as triamcinolone acetonide suspension injected directly into a lesion on or immediately below the skin.

In New Zealand triamcinolone is marketed as Kenacort-A, and is available in 2 strengths: 10mg per ml (Kenacort-A 10), or 40mg per ml (Kenacort-A 40). Triamcinolone acetonide is marketed as Kenalog in the USA.

Shorter-acting corticosteroid preparations, such as dexamethasone or betamethasone acetate, are sometimes administered in combination with triamcinolone.

What are intralesional steroids used for?

Intralesional steroid injection may be indicated for the following skin conditions:

Intralesional steroid injection for alopecia areata
Regrowth after intralesional steroid into alopecia areata

What are the advantages of intralesional steroids?

Intralesional administration of corticosteroids is used to treat a dermal inflammatory process directly. In contrast to topical steroids, intralesional steroids:

Other uses for triamcinolone acetonide injection

Triamcinolone is also sometimes used intramuscularly as an alternative to oral corticosteroids, for example for seasonal hay fever, or to treat a chronic skin disorder such as atopic dermatitis or lichen planus.

Typical intramuscular doses are 0.5–1 mg/kg body weight (40-80 mg for typical adult), which may be repeated every 30 days for 3 to 6 months.

Triamcinolone injections can also be used in the treatment of tendonitis, arthritis and synovitis.

Contraindications to intralesional steroid

Intralesional steroids should not be injected at the site of active skin infection e.g., impetigo (school sores) or herpes simplex (cold sores).

They must not be used if there is a previous history of triamcinolone hypersensitivity (allergy).

When large doses of triamcinolone acetonide injections are used as an alternative to oral steroids such as prednisone, they are considered to be systemic steroids. These should be avoided in patients with the following disorders.

Administration of intralesional steroid

Intralesional triamcinolone is injected directly into the skin lesion using a fine needle after cleaning the site of injection with alcohol or antiseptic solution. The injection should be intradermal, not subcutaneous, to avoid causing a dent in the skin.

The initial dose per injection site will vary depending on the lesion being treated. Generally, 0.1 mL is injected per square centimetre of involved skin. It can be repeated every 4-8 weeks.

The triamcinolone can be full strength (e.g. 10mg/mL or 40mg/mL) or diluted with normal saline or local anaesthetic. Typical regimes include:

The injections may be repeated monthly for a few months while the lesions are active.

Intralesional steroid injection Intralesional steroid injection
Intralesional steroid injection

Side effects arising at the site of intralesional steroid injection

Side effects and risks of intralesional triamcinolone may be separated into early and delayed effects.

Early effects tend to be self-limited. They include:

Delayed adverse effects include:

Lipoatrophy due to intralesional steroid injection
Lipoatrophy
Lipoatrophy due to intralesional steroid injection
Leukoderma
Lipoatrophy and leukoderma due to intralesional steroid injection
Lipoatrophy and leukoderma
Side effects of intralesional steroid injection

Systemic side effects of triamcinolone injections

Allergic reactions are very rare, and dose independent but may include local or generalised urticaria (wheal and flare), and in more severe cases, anaphylaxis (angioedema, swollen face/tongue, respiratory distress, hypotension/shock).

Other systemic side-effects are not likely to follow intralesional injection of localised skin disease because the dose used is very small.

However, the following potentially serious conditions have been reported from intramuscular injection of large doses of triamcinolone acetonide.

Related information

References:

On DermNet NZ:

Other websites:

Books:

See the DermNet NZ bookstore

Author: Dr Chin-Yun Lin, Dermatology Registrar, Waikato Hospital, Hamilton, New Zealand.

Note:

The New Zealand approved datasheet is the official source of information for this prescription medicine, including approved uses and risk information. Check the New Zealand datasheet on the Medsafe website.

DermNet NZ does not provide an online consultation service.
If you have any concerns with your skin or its treatment, see a dermatologist for advice.